Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis
作者: Minh Vu Chuong NguyenAthan BailletXavier RomandCandice TrocméAnaïs CourtierHubert MarotteThierry ThomasMartin SoubrierPierre MiossecJacques TébibLaurent GrangeBertrand ToussaintThierry LequerréOlivier VittecoqPhilippe Gaudin
作者单位: 1EA 7408, University Grenoble Alpes, GREPI, 38400 Saint-Martin-d’Hères, France
2Rheumatology Department, centre hospitalier universitaire Grenoble Alpes, hôpital Sud Echirolles, 38130 Echirolles, France
3Pôle biologie, hôpital Michallon, centre hospitalier universitaire Grenoble Alpes, 38700 La Tronche, France
4Department of Rheumatology, Saint-Etienne University Hospital, 42270 Saint-Etienne, France
5Inserm 1059, SAINBIOSE University of Saint-Etienne, 42270 Saint-Etienne, France
6Service de rhumatologie, hôpital G.-Montpied, centre hospitalier universitaire Clermont-Ferrand, 63003 Clermont-Ferrand, France
7Department of Immunology and Rheumatology, Immunogenomics and Inflammation Research Unit EA 4130, University of Lyon, Edouard Herriot Hospital, 69003 Lyon, France
8Rheumatology Department, centre hospitalier Lyon-Sud, 69310 Pierre-Bénite, France
9TIMC-IMAG Laboratory UMR 5525, CNRS, université Grenoble Alpes, 38041 Grenoble, France
10Inserm CIC/CRB1404, Normandie Univ, UNIROUEN, Inserm U 1234, Rouen Universi
刊名: Joint Bone Spine, 2018
来源数据库: Elsevier Journal
DOI: 10.1016/j.jbspin.2018.05.006
关键词: BiomarkersRheumatoid arthritisTNFα inhibitorEtanerceptAdalimumabInfliximabPredictionPrealbuminPlatelet factor 4S100A12
原始语种摘要: Abstract(#br)Objectives(#br)Tumour necrosis factor-alpha inhibitors (TNFi) are effective treatments for Rheumatoid Arthritis (RA). Responses to treatment are barely predictable. As these treatments are costly and may induce a number of side effects, we aimed at identifying a panel of protein biomarkers that could be used to predict clinical response to TNFi for RA patients.(#br)Methods(#br)Baseline blood levels of C-reactive protein, platelet factor 4, apolipoprotein A1, prealbumin, α1-antitrypsin, haptoglobin, S100A8/A9 and S100A12 proteins in bDMARD naive patients at the time of TNFi treatment initiation were assessed in a multicentric prospective French cohort. Patients fulfilling good EULAR response at 6 months were considered as responders. Logistic regression was used to determine...
全文获取路径: Elsevier  (合作)
影响因子:2.748 (2012)

  • factor 因素
  • treatment 处理
  • baseline 基线
  • arthritis 关节炎
  • values 价值观
  • predict 预见
  • ratio 
  • platelet 血小板
  • could 能够
  • effective 有效的